Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of lncrna and its application as prostate cancer detection marker or prostate cancer prognosis recurrence marker

A prostate cancer and sequence technology, applied in the field of biomedicine, can solve problems such as differences in the pathological detection rate and incidence rate of prostate cancer

Inactive Publication Date: 2018-07-06
ZHEJIANG SCI-TECH UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the pathological detection rate of prostate cancer and the empirical clinical incidence rate are very different, and there is no effective way to guide the recurrence of prostate cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of lncrna and its application as prostate cancer detection marker or prostate cancer prognosis recurrence marker
  • A kind of lncrna and its application as prostate cancer detection marker or prostate cancer prognosis recurrence marker
  • A kind of lncrna and its application as prostate cancer detection marker or prostate cancer prognosis recurrence marker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0073] Example 1 The relationship between the quantitative analysis of the expression of LncRNA in prostate cancer tissue and the age of the disease

[0074] In the database website http: / / www.cbioportal.org / , the pathological information of prostate cancer tissue and prostate cancer adjacent tissue samples according to "Mutations Putative copy-number alterations from GISTIC mRNA Expression z-Scores (RNA Seq V2RSEM)" to obtain the complete pathological information of 499 prostate cancer samples, as shown in Table 1 below:

[0075] Table 1 Clinicopathological information of patients with prostate cancer and adjacent tissues

[0076]

[0077] According to the disease age in the pathological information of 499 prostate cancer samples, the prostate cancer samples were divided into three age groups (figure 1 .

[0078] from figure 1 It can be seen that the expression ratio of LINC00657, SNHG15, FTX, MIR17HG in the high age group is higher than that in the low age group, whi...

Embodiment 2

[0079] Example 2 LncRNA expression in prostate cancer tissue and analysis of sequencing results on pathological grading

[0080] According to the TCGA tumor database, the 499 samples of prostate cancer samples screened in Example 1 that have been subjected to RNA sequencing were analyzed, and the analysis was carried out according to 2,530 LncRNAs approved in http: / / www.genenames.org / . LncRNA expression in prostate cancer samples with tumor size T1 (86 cases) and T2 (67 cases), the results of the investigation can be found in figure 2 .

[0081] Depend on figure 2 It can be seen that the expression ratio of COLCA1, SNHG15, FTX, and MIR17HG in the T1 stage of prostate cancer was 20%, 60%, 20% and 40% lower than that in the T2 stage, while the expression ratio of LINC00657 in the T1 stage of prostate cancer was lower than that in the T2 stage. period was significantly higher by 1.2 times.

[0082] These five LncRNA molecules, especially COLCA1, SNHG15, FTX, and MIR17HG, can...

Embodiment 3

[0083] Example 3 Differences in the expression levels of LncRNAs between recurrent and non-recurrent prostate cancer tissues

[0084] Analyzing the prognosis of prostate cancer samples in Table 1, it was found that there were 9 cases with prognosis recurrence, namely: TCGA-EJ-5524, TCGA-EJ-5525, TCGA-EJ-5526, TCGA-CH-5791, TCGA-M7- A724, TCGA-J4-A67N, TCGA-CH-5751, TCGA-G9-6332, TCGA-CH-5743, and the remaining 490 cases had no recurrence.

[0085] According to the high-throughput sequencing results of 499 prostate samples, the expression levels of target LncRNAs in relapsed and non-relapsed cases were analyzed, and it was found that COLCA1 (RQ=1.785), LINC00657 (RQ=1.218), SNHG15 (RQ=1.072), FTX (RQ=1.198) and MIR17HG (RQ=1.382) are significantly highly expressed in prostate cancer recurrence cases, so the expression of these five LncRNAs in prostate cancer tissue can significantly predict the prognosis of recurrence patients, and can better guide prostate cancer Clinical treat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses LncRNA and an application thereof as a prostatic cancer detection marker or prostatic cancer prognosis recurrence marker. The LncRNA is at least one of the following nucleic acid molecules: (1) Linc00657, SNHG15, FTX, MIR17HG and COLCA1; (2) nucleic acid molecules having 90 percent or more homology with the LncRNA. The LncRNA is discovered to have no expression or low expression in prostate normal tissues or para-carcinoma tissues but to have third-times or more expressions in the prostatic cancer tissues than that in the normal tissues or the para-carcinoma tissues, thereby being used as the prostatic cancer detection marker, prostatic clinical staging marker or prostatic cancer prognosis reoccurrence marker; the LncRNA can assist to judge the occurrence situation of the prostatic cancer, the size of a prostatic cancer tumor or the prognosis recurrence situation of the prostatic cancer and has characteristics of wide detection spectrum, high sensitivity, low detection cost and the like.

Description

technical field [0001] The invention belongs to the field of biomedicine, and specifically relates to an LncRNA and its application as a prostate cancer detection marker or a prostate cancer prognosis and recurrence marker. Background technique [0002] There are about 20,000 to 30,000 genes that encode proteins in the human body, accounting for only 2% of the human genome, and the remaining 98% of genomic DNA that does not encode proteins was originally considered to be nonfunctional and garbage in organisms, often called "Junk DNA". [0003] However, current research shows that most of these junk DNA can be transcribed to produce non-coding RNA (non-coding RNA, ncRNA). According to the size of mature transcripts, ncRNA can be divided into small molecule ncRNA (such as siRNA, miRNA, piRNA, etc.), medium-length ncRNA (70-200nt) and long ncRNA (long ncRNA, LncRNA, >200nt). [0004] At present, most of the research in the field of ncRNA is small molecule ncRNA, while the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/113C12Q1/6886C12N15/11C40B40/06
Inventor 丁先锋莫寅元
Owner ZHEJIANG SCI-TECH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com